Syngene International Limited has informed the Exchange about Investor Presentation
Ref: Syn/CS/SE/IP/2025-26/Nov/04
November 06, 2025
To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268
Dear Sir/Madam,
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2025. The Company will use this presentation for any meeting scheduled with analysts or institutional investors.
The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.
This is for your information and records.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
______________ Chethan Yogesh Company Secretary and Compliance Officer
Enclosed: Investor Presentation.
Phase,
B o m m a s a n d r a I n d u s t r i a l A r e a , I V
B o m m a s a n d r a I
Investor Presentation
November 2025
Safe harbour
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.
Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Putting Science to Work
2
Contents
1
2
3
4
5
Q2 FY26 Highlights
Syngene – Putting Science to Work
Syngene strengths
Financials
Shareholding and Share Information
Putting Science to Work
3
1
Q2 FY26 Highlights
Q2 and H1 FY26 performance
Operating Highlights
Q2 FY26 Financial Highlights
• The Company secured its first global phase III clinical trial from a U.S.-based
biotech company. The trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene’s growing capabilities in the global clinical trials market.
• Syngene has also expanded its clinical trials footprint to Australia, New Zealand,
the UK, Sri Lanka, and Eastern Europe, strengthening global trial execution capabilities through strategic partnerships with well-established CROs in these regions.
• Syngene will expand its biologics facility in Bengaluru with a GMP bioconjugation suite to provide fully integrated, end-to-end manufacturing of ADCs. The suite will accelerate development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site and complement Syngene’s existing commercial capabilities in payload and linker manufacturing.
•
Progress at the Bayview biologics manufacturing facility in the U.S. remains on track, with revalidation, integration, and staff recruitment advancing towards operationalization in the second half of the year.
• The sustainability assessment of Syngene’s laboratories, conducted by US
sustainability certification expert, My Green Lab (MGL), earned the highest level ‘Green Certification’ with a score exceeding 94%. Further, Syngene strengthened its position as a global sustainability leader, with its EcoVadis 2025 score rising to 74/100, up from 66 last year. This places the Company in the 91st percentile, ranking it among the top companies worldwide for sustainability practices..
Revenue from Operations Rs 911 Cr ( 2% Y-o-Y) ~USD 103 Mn
Operating EBITDA margin 22% (27% in Q2 FY25)
Reported PAT before exceptional items : (-37%YoY)
H1 FY26 Financial Highlights
Revenue from Operations Rs 1,785 Cr ( 6% Y-o-Y) ~USD 204 Mn
Operating EBITDA margin 23% (25% in H1 FY25)
Reported PAT before exceptional items : ( -4% YoY)
Putting Science to Work
5
2
Syngene – Putting Science to Work
Partner in innovation: #Putting Science to Work
Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients
We offer integrated solutions across research, development and manufacturing
Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals
Our team includes more than ~5,600 scientists out of total 8,200+ headcount, operating across 4 global state-of-the-art campuses located in India’s leading life science hubs: Bangalore, Mangalore and Hyderabad & USA (Baltimore)
Established track record in discovery research and development/ manufacturing for small and large molecules
Putting Science to Work
7
Our journey so far
Globalization and strategic collaboration • Expanded into formulations development • Contract with Endo Pharmaceuticals to develop novel anti cancer
biological therapeutic molecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion
Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status
by the Government of India
1993 – 2000
2010 – 2014
2001 – 2009
Expansion • Expanded service offerings to
include chemical development, safety assessment, biologics development
• Collaboration with BMS to set
up BBRC, Syngene’s first dedicated R&D Center
2015 – 2018
IPO and further collaborations • IPO and listing • Collaboration with Amgen to set up a dedicated R&D center
2019 – 2025
Continued investments and growth • Expanded collaboration with BMS, Amgen and
Zoetis
• Expansion of Integrated Drug Discovery platform • Laboratory capacity expansion in Bangalore and Hyderabad
• Expansion in Mangalore for commercial API
manufacturing
• Capacity and capability addition in Biologics
manufacturing
• Entered in long-term partnership with Zoetis for
Biologics commercial-scale manufacturing • Acquired multi-modal biologics manufacturing
facility from Stelis Biopharma Ltd
• Acquired 17 acres land in Hyderabad to support
long term growth in research business
• Acquired, state of the art first biologics site in
Baltimore, USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines taking Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services
Putting Science to Work
8
Key facts and figures
~400 active clients
14 out of top 20 pharma companies are clients
400+ patents held with clients
World class infrastructure International presence with global campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards
Rs. 3,642 Cr (~US$430* Mn) FY25 Revenue from operations
Rs. 475 Cr** FY25 PAT
8,235 headcount including 5,641 talented scientists
92% energy from renewable sources
* All figures are as on March 31, 2025 / FY2025
**before exceptional items
Putting Science to Work
9
Syngene – one of the largest integrated CRDMO players in India
One-stop platform for integrated drug discovery, development and manufacturing across modalities
Expanding capacity
Building capabilities for future
Building partnerships
(in Million sq. ft.)
2.5+
(#)
8,235
(#)
0.9
3,526
~400
250+
March’16 FY16
March’25 FY25
March’16 FY16
March’25 FY24
March’16 FY16
March’25 FY24
More than doubled infrastructure that is qualified to meet international standards
~3x employees from FY16 comprising talented scientists
• Expanded laboratory capacity in Bangalore and Hyderabad
• 5,600+ scientists comprising PhDs, MS
• Expanded to Mangalore for commercial API manufacturing
• Acquired land in Hyderabad for long term growth in research
business
• Acquired multi-modal biologics facility from Stelis Biopharma Ltd
• Acquired first biologics site in the USA from Emergent
Manufacturing Operations Baltimore, LLC
• US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC
accredited and GLP certified facilities
• Skills and experience to become trusted thought
partner in cutting-edge research
• Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
• Proven success in delivering integrated CMC
programs and clinical candidates
Over 50% increase in active clients 14 out of top 20 pharma companies are clients
• Expanded partnership with big pharma companies
•
Increasing contribution from emerging biotech companies in research services with share of total revenue from US emerging biotech increasing from 10% in FY21 to 14% in FY25
• Expanded into commercial manufacturing in Biologics
with Zoetis
• Enhanced BD presence across key value clusters
including US and Europe
• 25-year strategic partnership with BMS – established BBRC, India’s first and largest dedicated R&D center
10
3-pronged growth strategy across diversified platform
Research Services (CRO)
Discovery Services
Dedicated R&D Centers
Clinical Development
Large Molecule CDMO
Small Molecule CDMO
Ring-fenced infrastructure for exclusive operations for an individual client
Comprehensive research services through trials conducted on both healthy volunteers and patients
Dedicated multi-disciplinary team of scientists
Access to entire Syngene ecosystem for specialist research and development operations
Regulated bioanalysis (small & large molecules, peptides, ADC's), Central Lab, Clinical Data Management & Biostatistics as allied services
Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
SynVent - proprietary platform for Integrated Drug Discovery
SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies
Process development
Manufacturing of large molecules for clinical/commercial supplies
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
cGMP-compliant facilities
State-of-the art Biologics manufacturing facilities with international presence
Drug substance and drug product development
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules
Manufacturing of small molecules for commercial supplies
State-of-the art API manufacturing facility
Putting Science to Work
11
Our Strategy
Research Services
Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre- clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.
Development and Manufacturing Services – Large Molecules
Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.
Operational Excellence
People
Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction.
Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation
Development and Manufacturing Services – Small Molecules
Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider
Environmental, Social and Governance (ESG)
Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations
Putting Science to Work
12
3
Syngene strengths
Syngene strengths
A global scale CRDMO player •
Integrated Drug Discovery, Development and Manufacturing service provider
• Small and large molecules, ADCs, oligonucleotides • Listed on Indian Stock Exchanges (NSE and BSE)
Solutions through innovation • IP fully assigned to clients • Track record of data management and
security
• Over 400+ patent filings by clients recognizing Syngene scientists
Quality matters • Fully digitized quality organization • Strong compliance track record with global regulators • US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC
accredited and GLP certified facilities
• 111 client and regulator audits in the last financial year
Science in our DNA • Global presence : India life science hubs: Bangalore,
Mangalore and Hyderabad & Baltimore, USA
• ~5600+ qualified scientists including ~500 PhDs (8,200+ total
headcount) Resilient supply chain management
• • 2.5 Mn+ sq. ft world-class R&D and manufacturing
infrastructure
Blue chip client list • ~400 active clients • Partnering with large / mid-size / emerging
biopharma and other industries
• Clients concentrated in US, Europe & Japan • Track record of working with diverse industry
sectors
Making a difference • Partnerships have delivered numerous clinical candidates • Delivery history for integrated CMC programs up to clinical trials and beyond
Putting Science to Work
14
Experienced workforce: building capabilities and careers
8,235 total headcount
Inspiring technical excellence and providing opportunities to grow
5,641 scientists delivering high quality solutions – create a competitive edge
Empowering our workforce
PhDs Master's Degree
Others
7%
Continuous learning & development
42%
51%
Shaping a culture of belonging
All figures are as on March 31, 2025
• Thrive 360: A holistic approach to employee well being addressing physical, mental and
emotional, social, financial and professional health through targeted initiatives.
• Our corporate initiatives contribute to both professional fulfillment and organizational success.
Moving beyond traditional evaluations, our forward-looking approach continues to foster meaningful conversations that celebrate achievements while paving the way for future growth and success
• Enhancing managerial and leadership capabilities through our multi-pronged approach which
ensures leaders at all levels are equipped to inspire, develop, and retain top talent
• Enhancing our technical learning framework by establishing an enterprise-wide Scientific Skills Development Academy. This centralized academy will standardize and elevate our upskilling approach, integrating advanced curricula in emerging research methodologies with hands-on application module
• A strong and well-structured Diversity, Equity, and Inclusion strategy lays the groundwork for
making Syngene a fair, reputed and high performing organization
• We welcome diverse people from different backgrounds, having varied capabilities and offering
a wide range of perspectives
• 26% of our workforce is female and 6% of senior management positions are held by women
Putting Science to Work
15
Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs…
HQ campus at Bangalore, India 90 Acres (3,64,217 sq. mt) where most of Syngene’s capabilities are housed today
Fully functional R&D Centre at Genome Valley, Hyderabad, India
USA based Biologics facility Bayview, Baltimore, USA
Biologics Discovery development & and manufacturing plants in Bangalore, India
API manufacturing Commercial manufacturing to support product launch located at Mangalore, India
Putting Science to Work
16
We currently operate a range of successful collaboration models
Dedicated R&D Labs
Full time equivalent (FTE)
Fee For service (FFS)
Risk / Reward Model
• Customers receive ring-fenced infrastructure customized to their research needs
• Dedicated scientific and support teams work exclusively on the customer’s projects
• Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation
• A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer’s projects
• Deliverables and team
composition evolve as the project progresses to align with changing requirements
• Agreements are typically
renewed annually, ensuring continuity and flexibility
• Services are provided within a defined scope
• Flexible, on-demand
personnel and research infrastructure are allocated to meet project objectives
• Engagements can be short- term or long-term, based on project requirements
• A milestone-driven approach covering a portfolio of research projects
• Customers benefit
from reduced upfront costs, with payments tied to predefined success milestones
5
Outcome – based model with Service Level Agreement
• A contract structured
around the achievement of predefined outcomes
• Linked to specific
productivity goals to ensure performance-driven results
… and are open to any single or combination of above
Putting Science to Work
17
Our experience spans multiple industry segments and partners us with global leaders across the world…
Large & Mid-Sized BioPharma
Emerging BioPharma (EBP)
Animal Health
AgroChem
CPG
Chemicals/ Polymers
Note : This is a representative selection of the customers Syngene works with. We work with ~ 400 customers across industry segments .All product names, logos, brands, trademarks and registered trademarks are the property of their respective owners
Putting Science to Work
18
Operational robustness driving strategy execution
Continuous improvement embedded in operations driven by certified operational leaders Six Sigma Black Belt certified staff in each service line and support function Green belt certified staff across operations 99% of employees white belt certified
Quality management system: digitized and audit-ready 111 customer and regulator audits in the last financial year 5 successful USFDA audits in the last 5 years
Client-focused commercial organization Leaders based in the US, Europe, UK and Asia close to client locations
Focused execution through strong Project Management Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects
Digital as a differentiator AI capability in all research teams Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance
Strategic Sourcing that makes a difference Effective global collaboration with 2,800+ suppliers across 30 countries
China-independent supply chain development continued through strategic sourcing from the Indian ecosystem, and engagement with global suppliers to establish operations in India
Putting Science to Work
19
Syngene digital initiatives aimed at driving innovation and operational
At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.
A key initiative, Project VEGA, aims to automate and integrate core business processes, enhancing Syngene’s digital presence and customer engagement.
Comprehensive 1-3-5-year roadmap to future-proof operations and build next- generation digital capabilities, with an emphasis on AI adoption
Accelerating Digital Transformation at Syngene
Driving Enterprise- Wide Transformation
Strengthening Scientific Operations
Automate workflows, eliminate errors, and improve execution quality
Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements
“Fail fast” approach to AI and GenAI, launching small-scale pilots to quickly test feasibility, assess early outcome
Enabling AI- Powered Productivity
Fortifying Infrastructure and Information Security
Advanced IT and cybersecurity landscape with a One-Click Disaster Recovery system, CDC & ISWG
Putting Science to Work
20
Committed to safety and sustainability
Safety is our first priority
•
•
•
•
•
Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
Risk assessments are an integral part of our operation
Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
Lost time injury frequency rate (LTIFR ): 0.00
36,737 hours of EHSS training
ESG Ratings
ESG Rating Agency
Ecovadis
CDP
2025
Silver
2024
Bronze
Climate Action – ‘B’ Water Security- ‘B’
Climate Action – ‘C’ Water Security- ‘D’
Sustainalytics
12.4 Low Risk
12.4 Low Risk
MSCI
A
BBB
Committed to environmental protection
•
•
•
•
•
•
•
•
Committed to Science-based targets for greenhouse gases
95% of total hazardous and non-hazardous waste recycled
92% of energy procured from green energy sources
1,296 MT equivalent CO2 savings from energy conservation
73,207 MT equivalent CO2 reduction in GHG emissions
64% YoY freshwater savings achieved
1,04,413 KL fresh water saved from recycling, reusing and rainwater harvesting
11,433 KL water rainwater harvested
Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development Refer to the Annual Report on our website to know more All figures are as on March 31, 2025, unless otherwise specified
Putting Science to Work
21
Accreditations
• USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities.
• GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory
• GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment
• USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility
•
•
ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility
ISO 9001:2015, 14001:2015, 45001:2018 and ISO/IEC 27001:2022 accreditations.
Putting Science to Work
22
We have consistently received industry recognition for our scientific capability and business excellence
EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide.
•
CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma
•
•
CMO Leadership Award Champion 2022 - Presented by Life Science Leader and Outsourced Pharma
• Golden Peacock Award for Excellence in Corporate Governance for 2021 by the Institute of
• Asia Pacific Biologics CMO Excellence Awards 2024 : Adjudged Best Biologics CMO in South Asia by IMAPAC • Winner under the Reliability and Compatibility categories for exceeding customer expectations at CDMO
Leadership Awards 2024
Directors at the 'Golden Peacock Awards Ceremony’
• Declared champion by the Institute of Supply Chain Management (ISCM) at the Pharma Supply Chain
•
•
The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for ‘Best Unique or Innovative Leadership Program’ and ‘Best Advance in Compliance Training’
The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for
•
•
Management 5.0 summit.
Award for Excellence in Environment Health and Safety (EHS) practices at CII-SR EHS Excellence Awards 2023
Awarded India’s Best Managed Company by Deloitte
• Asia Pacific Biologics CMO Excellence Awards 2022 - For Quality •
Biopharma Honours Award 2022 - For Viral Testing Facility by Informa Markets
• Most Preferred Workplace 2022 - Award by MarksmenDaily.com
• Golden Peacock Award 2023: For risk management practices under the Pharmaceutical sector category. •
Best Overall Sustainable Performance (Pharmaceutical) 2023 at the 2nd Edition India Sustainability Conclave & Awards 2023
2021
2022
2023
2024
2025
• Dream Companies to Work Award at the 29th Edition of the World HRD Congress
• Golden Peacock National Quality
Awards.
• Asian Leadership Award for Excellence in Branding and Marketing in the Contract
Research Development and Manufacturing category
•
•
•
•
•
CRISIL awards Syngene Top score among Indian Pharma - for Environment Safety Governance (ESG)
Syngene ranked #69 in Fortune India magazine's list of 'Top 100 Indian wealth creators 2021’
India Pharma Awards 2021 for Operational Excellence–Manufacturing organized by Informa Markets, India
Best Governed Company in the Listed Segment: Medium Category at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
Best Corporate Foundation Award at the World CSR Congress
Award 2023 For meeting the overall requirements of the Golden Peacock Excellence Model
•
Biopharma Excellence Awards 2023 For Best Contract Development and Manufacturing Organization (CDMO)
•
•
•
•
CDMO Leadership Award 2025 : Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications
Biopharma Excellence Awards 2025 (India Edition) : Adjudged best bioprocessing supplier, analytical services, by IMAPAC.
Pharma Supply Chain Champion (mid-sized firms) 2025 : Declared Pharma Supply Chain Champion among mid-sized pharma and API firms in the Institute of Supply Chain Management (ISCM) rankings for 2025
‘World’s Most Sustainable Companies 2025’ by TIME Magazine & Statista : Ranks #1 among Indian pharma & biotech firms , Top 10 among all Indian companies across all sectors & Among the top 20 most sustainable life sciences companies worldwide
• NAMC Gold Award for Biologics Manufacturing Excellence at the National
Awards for Manufacturing Competitiveness (NAMC)
Note : This is a representative selection of awards received by Syngene and is not an exhaustive list
Putting Science to Work
23
Robust risk management framework
Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance.
Risk Owner
Executive Committee
Risk Management Committee
Board of Directors (BOD)
•
•
•
Continuously identify, assess, and monitor risks
Develop, implement, and update mitigation plans and risk registers
Establish and maintain risk management policies and procedures
•
Review and recommend enterprise-level risks and framework changes
• Oversee and ensure implementation of mitigation plans with defined thresholds
• Monitor risk movements,
escalate as needed, and support operational execution
•
•
•
Approve and oversee the company-wide risk management and business continuity framework
Define risk appetite, tolerance, and critical exposures
Ensure an optimal balance between risk and reward
•
Define and review the company’s risk tolerance and overall policy
• Oversee and guide
enterprise risk management practices
•
Ensure alignment with strategic objectives
Refer Annual report for complete risk profile and risk mitigation strategy
Putting Science to Work
24
4
Financials
Q2 FY26 financial highlights
All figures in Rs. Mn unless otherwise specified
Particulars
Q2FY26 Q2 FY25 YoY change Q1 FY26 QoQ change
Balance Sheet Highlights
Revenue from operations
9,106
8,910
Other income
Reported revenue
Material costs
Staff costs
Other direct costs
Other expenses Foreign exchange (gain)/loss, net EBITDA
154
9,260
2,385
3,072
251
165
9,075
2,366
2,713
241
1,285
1,185
2%
-7%
2%
1%
13%
4%
8%
8,745
177
8,922
2,177
2,915
260
1,281
118
-43
-374%
48
2,149
2,613
-18%
EBITDA Margin Depreciation and Finance Cost PBT
Tax PAT before exceptional items PAT Margin
PAT after exceptional items
23.2%
28.8%
1,297
1,240
852
181
671
7.2%
671
1,373
312
1,061
11.7%
1,061
5%
-38%
-42%
-37%
-37%
2,241
25.1%
1,228
1,013
146
867
9.7%
867
As on 30th September 2025
All figures in Rs. Mn unless otherwise specified
Shareholders’ funds
Net Fixed assets
Other net assets (1)
Net cash/(debt) (2)
Total Use of Funds
47,349
40,382
-3,216
10,183
47,349
4%
-13%
4%
10%
5%
-4%
0%
146%
-4%
6%
-16%
24%
-23%
-23%
1 ) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity (2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year
Putting Science to Work
26
H1 FY26 financial highlights
All figures in Rs. Mn unless otherwise specified
Particulars
H1 FY25
H1 FY26
YoY change
Revenue from operations
Other income
Reported revenue
Material costs
Staff costs
Other direct costs
Other expenses
Foreign exchange (gain)/loss, net
EBITDA
EBITDA Margin
Depreciation and Finance Cost
PBT
Tax
16,807
17,851
346
331
17,153
18,182
4,701
5,237
496
4,561
5,987
511
2,236
2,567
-10
4,493
26.2%
2,426
2,067
461
166
4,390
24.1%
2,525
1,865
327
PAT before exceptional items
1,606*
1,538
PAT Margin
PAT after exceptional items
9.4%
1,818
8.5%
1,538
6%
-4%
6%
-3%
14%
3%
15%
-1806%
-2%
4%
-10%
-29%
-4%
-15%
*Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim
Putting Science to Work
27
5
Shareholding and Share Information
Syngene and Biocon Group
Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India’s first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services
Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene
Integrated services: • • • Manufacturing
Research Services Development and for
small/large molecules
• • •
•
Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs
Putting Science to Work
29
Shareholding and Share Information
Syngene’s shareholders*
1%
47%
Promoter & Promoter Group
53%
Public
ESOP Trust
Syngene’s Share Information*
NSE Ticker
BSE Ticker
Market Cap (Rs. Mn)
% free-float^
Free-float market cap (Rs. Mn)
Share Outstanding (Mn)
SYNGENE
539268
2,50,971
47%
1,18,750
403
• As on 30th September 2025 •
^ Free float includes shares held by public and in ESOP Trust
Putting Science to Work
30
For more details
Visit our website www.syngeneintl.com
https://www.linkedin.com/company/syngene-international-limited
https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ
IR Contact: Nandini Agarwal / Shubham Jain +91 7838382527 / +91 6377651994 investor@syngeneintl.com nandini.agarwal@syngeneintl.com shubham.jain@syngeneintl.com
Media Contact: Shotorupa Ghosh +91 8450977080 shotorupa.ghosh@syngeneintl.com
Putting Science to Work
31